Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Laboratoire UMR-CNRS 5510 MATEIS, INSA, Université Lyon 1, Villeurbanne, France.
Retina. 2024 Oct 1;44(10):1807-1813. doi: 10.1097/IAE.0000000000004165.
To investigate the variation of interleukin-10 (IL-10) levels in the aqueous humor (AH) of patients with vitreoretinal lymphoma (VRL) throughout therapy and follow-up and analyze the relation of these variations with VRL clinical course and relapse.
This study retrospectively included consecutive patients diagnosed with VRL in a single center. AH IL-10 samples and patient clinical course were evaluated. The response to treatment was evaluated according to the criteria set by the International Primary Central Nervous System Lymphoma Collaborative Group.
A total of 59 eyes of 34 patients were included. Interleukin-10 levels decreased significantly at first AH sample after therapy induction (median [IQR] 3.0 [2.8-3.6] months) among patients in complete clinical remission (P < 0.001). Among patients in complete clinical remission with residual detectable IL-10 in AH after therapy induction (85.3% systemic chemotherapy, 11.8% intravitreal methotrexate, 2.9% palliative care), 87.5% experienced ocular relapse within 5 years. The detection of IL-10 in AH at the first visit after induction for complete clinical remission obtained a sensitivity of 77.8% (95% CI 0.45-0.96) and a specificity of 96.4% (95% CI 0.82-0.99) to predict ocular relapse. For relapsing eyes (N = 26), IL-10 significantly increased between the last IL-10 measurement and the time of the first ocular relapse (P < 0.001). In 76.0% of cases, an increase in IL-10 was detected earlier than clinical relapse with a mean (SD) of 4.0 (2.4) months.
The present study suggested the usefulness of IL-10 in the prognosis of VRL. This study showed a relation between IL-10 in AH and tumoral activity, and for the first time with disease relapse.
研究在治疗和随访过程中玻璃体内（AH）白细胞介素-10（IL-10）水平在眼内淋巴瘤患者中的变化，并分析这些变化与眼内淋巴瘤临床病程和复发的关系。
本研究回顾性纳入了在单中心诊断为眼内淋巴瘤的连续患者。评估 AHIL-10 样本和患者临床病程。根据国际原发性中枢神经系统淋巴瘤合作组制定的标准评估治疗反应。
共纳入 34 例患者的 59 只眼。在完全临床缓解的患者中，治疗诱导后首次 AH 样本中白细胞介素-10水平显著降低（中位数 [IQR]3.0[2.8-3.6]个月）（P<0.001）。在完全临床缓解且治疗诱导后 AH 中仍可检测到残留白细胞介素-10的患者中（全身化疗 85.3%，玻璃体内甲氨蝶呤 11.8%，姑息治疗 2.9%），87.5%在 5 年内发生眼部复发。在完全临床缓解的诱导后首次就诊时检测到 AH 中的白细胞介素-10，其预测眼部复发的敏感性为 77.8%（95%CI0.45-0.96），特异性为 96.4%（95%CI0.82-0.99）。对于复发的眼睛（N=26），在最后一次白细胞介素-10 测量和第一次眼部复发之间，白细胞介素-10 显著增加（P<0.001）。在 76.0%的病例中，白细胞介素-10 的增加早于临床复发，平均（SD）为 4.0（2.4）个月。
本研究提示白细胞介素-10在眼内淋巴瘤预后中的有用性。本研究显示了 AH 中白细胞介素-10与肿瘤活性之间的关系，并且首次与疾病复发相关。
